

Effect van voedsel op de farmacokinetiek van nilotinib: op maat naar een lagere dosering (NiFo-onderzoek)

Gepubliceerd: 20-02-2015 Laatste bijgewerkt: 19-03-2025

As food increases nilotinib bioavailability, intake of nilotinib with medium fat Dutch food is expected to increase the bioavailability to an extent that it will allow a reduction of the daily dose by about 30 percent. This both reduces costs...

Ethische beoordeling	Niet van toepassing
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON23914

Bron

NTR

Verkorte titel

NiFo-study

Aandoening

Chronic Myeloid Leukemia
Nilotinib

Ondersteuning

Primaire sponsor: VU University Medical Center

Overige ondersteuning: ZonMw

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The difference in pharmacokinetic parameters AUC, Cmax, and Cmin between fasted and fed administration of nilotinib.

Toelichting onderzoek

Achtergrond van het onderzoek

Primary Objective: To evaluate the effect of real-life food consumption on the pharmacokinetics of nilotinib in CML patients.

Exploratory Objective: To evaluate patient reported side effects and quality of life of CML patients using nilotinib at a lowered dose of 200 mg bid, administered with a meal.

Study design: Intervention study with a pre-test post-test design, in chronic phase CML patients using nilotinib at a dose of 300 mg bid. The AUC, Cmax and Cmin of nilotinib, administered as recommended on an empty stomach during a period of four days, will be compared with the AUC, Cmax and Cmin of nilotinib 200 mg bid, administered with a meal for a period of seven days. Patient will be instructed about their meals. The study is non-invasive: nilotinib concentrations will be measured by means of the dried blood spot (DBS) sampling method. Patients will be asked to complete a patient diary collecting data on the exact time of intake of nilotinib, exact time of blood sampling, consumption of food and side effects. Patients will be asked to fill out questions about quality of life. Overall study duration for the individual patient is 2 weeks.

Doel van het onderzoek

As food increases nilotinib bioavailability, intake of nilotinib with medium fat Dutch food is expected to increase the bioavailability to an extent that it will allow a reduction of the daily dose by about 30 percent. This both reduces costs substantially and allows for increased adherence to nilotinib simultaneously.

Onderzoeksopzet

1. Bloodsampling

On day 1 and 3 of the four day period of fasted intake and on day 4 and 7 of the seven day period of fed intake: blood sampling at 1, 2, 3, 4, 6, 9 and 12 hrs after nilotinib intake in the morning, and 1, 2, 3 and 4 hrs after nilotinib intake in the evening and before the nilotinib intake of the next morning.

On day 1 of the seven day period of fed intake: blood sampling at 1, 2 and 3 hrs after nilotinib intake.

2. Questionnaire

At baseline and after the seven day period of fed intake.

3. Patient diary

On day 1 and 3 of the four day period of fasted intake and on day 1-7 of the seven day period of fed intake.

Onderzoeksproduct en/of interventie

Nilotinib at a lowered dose of 200 mg bid, administered with a meal for a period of seven days.

The half-life of nilotinib is 17 hrs, which suggests that variability in pharmacokinetics, due to variability in the composition of meals, is limited. However, for safety reasons and to get insight into the effect of a high fat meal, patients will be asked to take nilotinib once with a high fat meal, to be planned at day seven (evening intake) of the seven day period of fed intake. A dietician will assist patients to select meals that fit into these guidelines.

Contactpersonen

Publiek

Clinical Pharmacology and Pharmacy
VU University Medical Center
PO Box 7057

J.G. Hugtenburg
Amsterdam 1007 MB
The Netherlands
00 31 20 4448090

Wetenschappelijk

Clinical Pharmacology and Pharmacy
VU University Medical Center
PO Box 7057

J.G. Hugtenburg
Amsterdam 1007 MB
The Netherlands
00 31 20 4448090

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Male or female patients at least 18 years of age;

- Chronic Myeloid Leukemia in chronic phase;
- Currently treated with nilotinib at 300 mg bid for at least 3 months;
- Stable clinical status;
- Written informed consent.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Patient is unable to fill out a patient diary;
- Patient has insufficient knowledge of the Dutch language.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	01-03-2015
Aantal proefpersonen:	20
Type:	Werkelijke startdatum

Ethische beoordeling

Niet van toepassing	
Soort:	Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 42074

Bron: ToetsingOnline

Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL4898
NTR-old	NTR5000
CCMO	NL50637.029.15
OMON	NL-OMON42074

Resultaten